A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

BACKGROUND: Vilazodone, a selective serotonin reuptake inhibitor and 5-HT(1A) receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorde...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Depress Anxiety
Egile Nagusiak: Gommoll, Carl, Durgam, Suresh, Mathews, Maju, Forero, Giovanna, Nunez, Rene, Tang, Xiongwen, Thase, Michael E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2015
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4676920/
https://ncbi.nlm.nih.gov/pubmed/25891440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/da.22365
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak